Hepatitis B-CpG Vaccine Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders.

IF 8.2 1区医学 Q1 IMMUNOLOGY

Clinical Infectious Diseases Pub Date : 2024-08-16 DOI:10.1093/cid/ciae320

Rachel K Russ, Haley M Vandehei, Maria I Golovkina, Harshitha Mogallapalli, Freddy Caldera, Mary S Hayney

引用次数: 0

Abstract

This prospective study enrolled healthcare workers (HCWs) who were nonresponders following at least 5 doses of aluminum-adjuvanted hepatitis B vaccine who received the 2-dose Heplisav-B (HepB-CpG) (Dynavax Technologies Corporation, Emeryville, CA) series. After 2 doses of HepB-CpG, 43/47 (91%) participants, and with 1 dose, 41/49 (84%) responded. HepB-CpG could be the preferred vaccine in HCW nonresponders. Clinical Trials Registration. Clinicaltrials.gov NCT04456504.

查看原文本刊更多论文

为乙型肝炎疫苗无应答的医护人员接种乙型肝炎-CpG 疫苗系列。

这项前瞻性研究招募了至少接种过 5 剂铝佐剂乙型肝炎疫苗后无应答的医护人员（HCW），让他们接种 2 剂 Heplisav-B (HepB-CpG) 系列疫苗。接种两剂 HepB-CpG 后，43/47（91%）的参与者有反应，接种一剂后，41/49（84%）的参与者有反应。HepB-CpG可能是高危工人无应答者的首选疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Infectious Diseases 医学-传染病学

CiteScore

25.00

自引率

2.50%

发文量

900

审稿时长

3 months

期刊介绍： Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.